NCT07528963

KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice

ENROLLING_BY_INVITATIONNAINTERVENTIONAL

Trial Details

Start: 2025-06-30Est. Completion: 2028-08-01

Enrollment target: 16 participants

Locations

University of Kansas Medical Center, Kansas City, Kansas, United States

Other microbiome trials you might be interested in

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasPhase 1Recruiting

Atypical Teratoid/Rhabdoid TumorEmbryonal Tumor With Multilayered RosettesEwing SarcomaDiffuse Intrinsic Pontine GliomaOsteosarcomaNeuroblastomaDIPG Brain Tumor

The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (…

Birmingham, United StatesEst. completion May 2033

View Trial →

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerPhase 2Recruiting

Metastatic Colorectal Cancer

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.